HSBC Holdings
NGM

HSBC Holdings’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

HSBC Holdings’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,757
Closed -$167K – 3225
2022
Q3 		$167K Buy
12,757
+2,432
+24% +$36.8K ﹤0.01% 2676
2022
Q2 		$132K Buy
+10,325
New +$143K ﹤0.01% 2988
2021
Q2 		– Sell
-8,996
Closed -$257K – 3124
2021
Q1 		$257K Sell
8,996
-2,306
-20% -$64.6K ﹤0.01% 2399
2020
Q4 		$340K Sell
11,302
-4,045
-26% -$88.5K ﹤0.01% 2486
2020
Q3 		$248K Buy
15,347
+4,591
+43% +$83.7K ﹤0.01% 2357
2020
Q2 		$212K Hold
10,756
– – ﹤0.01% 2329
2020
Q1 		$135K Buy
10,756
+385
+4% +$6.29K ﹤0.01% 2414
2019
Q4 		$190K Sell
10,371
-15,865
-60% -$232K ﹤0.01% 2825
2019
Q3 		$363K Buy
+26,236
New +$394K ﹤0.01% 2513

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HSBC Holdings's NGM Position: Q4 2022 in Review

HSBC Holdings sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2022, closing a stake of 12,757 shares — an estimated $167K sold.

HSBC Holdings first reported a position in NGM in Q3 2019 and held it in 9 quarters. The position peaked at $363K in Q3 2019. 125 funds tracked by Wall St. Rank hold NGM as of Q4 2022.

  • HSBC Holdings reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • HSBC Holdings sold 12,757 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $167K.
  • HSBC Holdings first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 9 quarters.
  • HSBC Holdings's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $363K in Q3 2019.
  • 125 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on HSBC Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.